Elder Pharma to focus on new therapeutics areas
The company would enter new therapeutics areas to drive growth.
Mumbai, December 27, 2013: After the Torrent Pharmaceutical deal in place, the Indian pharma firm Elder Pharmaceutical plans to focus on brand building and entering new therapeutics areas to drive its growth.
"After Torrent Pharmaceuticals' 2,004-crore acquisition deal, Elder Pharmaceuticals Ltd (EPL) plans to concentrate and build on its domestic business of anti-infectives, strengthen in-licence portfolio and grow its business in the UK and in Europe. It is also exploring the possibility of entering new therapeutics areas," the company said in a statement recently.
The managing director and chairman of the company, AlokSaxena said in a statement that the company expects an increase in the consolidated revenues and is looking at restructuring and restrategizing brands and people. The company will easily be able to increase its revenues and profitability, according to the statement from Saxena.
It may be noted here that Elder Pharma’s anti-infectives division has been contributing more than 10 per cent to the total revenue of the company and has been registering annual growth of over 12 per cent.